003020.SZ
立方制药
SZSE · Healthcare · C 制造业 · CN
CNY 17.49
−3.64%Year over year
Reported trailing growth
- Revenue
- +0.4%
- EBITDA
- —
- EBIT
- -6.8%
- EPS
- -2.8%
- Free cash flow
- +64.5%
- Operating cash flow
- +10.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -15.5%
- EBITDA
- +0.2%
- EBIT
- -8.8%
- Net income
- -7.6%
- EPS
- -13.2%
- Free cash flow
- +292.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026